Since the pandemic, scientists have been working hard to apply mRNA technology to cancer treatment, and now there are new progresses.
According to the latest news on Tuesday, Ginzburg, director of the Russian "Gamaleya" National Research Center for Epidemiology and Microbiology, said at a roundtable that Russia's domestically produced individualized cancer vaccine is ready and will be used to treat the first Russian patients after regulatory approval.
"All documents were submitted to the Ministry of Health some time ago, and we hope that in the near future, the Herzen Institute, the Blochin Institute and our institute will be able to obtain permission to produce the first individualized vaccines (for melanoma)," Ginzburg said. Accordingly, the patient population has been formed, their individualized genetic data has been identified, and we are ready to start treating them in a month to a month and a half through joint efforts. ”
As an experimental emerging therapy, mRNA cancer vaccines are designed to target malignant tumors using the patient's own genetic information. Using messenger RNA technology, vaccines can be tailored to a patient's specific cancer lineage, and theoretically better therapeutic outcomes.
It is reported that cancer vaccines in Russia are usedartificial intelligenceTumor parameters are analyzed and a drug "blueprint" is output, according to which the experts will prepare a vaccine within a week.
Ginzburg previously revealed that the first batch of individualized mRNA vaccines will be 60 melanoma patients at the Herzen Moscow Oncology Institute and the Blokhin National Oncology Research Center. The next target population for Russia's domestic personalized mRNA vaccine will be patients with non-small cell lung cancer.
Earlier this month, Veronika Skvortsova, director of the Federal Medical and Biological Administration (FMBA), said at the Eastern Economic Forum that Russia's cancer vaccine had successfully completed preclinical trials.
She emphasized that preclinical results confirm the safety of the vaccine, even with repeated administration, and show significant efficacy. The researchers observed a reduction in tumor size and a slowdown in tumor progression – between 60 and 80 percent, depending on the characteristics of the disease. Studies have also shown that vaccines improve survival.
It is worth mentioning that mRNA vaccines are also one of the areas where Russia and Western countries are "competing". According to documents on the Kremlin's official website, Skvortsova emphasized when reporting to Putin at the end of last year.The Russian mRNA platform significantly outperformed Moderna and in terms of effectivenessPfizerAt the same time, it is better controlled in terms of side effects.
https://finance.eastmoney.com/a/202509233521496619.html